Motilal Oswal retains ‘buy’ rating on Gland Pharma, raises target price amid inline revenue and strong growth outlook | cliQ Latest
Gland Pharma’s second-quarter performance has drawn a mixed response from investors and…
Gland Pharma’s second-quarter performance has drawn a mixed response from investors and…
